Dev Prasad
Stock Analyst at Lucid Capital
(4.73)
# 649
Out of 4,455 analysts
15
Total ratings
78.6%
Success rate
93.5%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dev Prasad
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNRX Quoin Pharmaceuticals | Initiated Coverage: Buy | $30 | $4.45 | +574.16% | 1 | May 4, 2026 | |
| ABOS Acumen Pharmaceuticals | Initiated Coverage: Buy | $6 | $2.36 | +154.24% | 1 | Dec 17, 2025 | |
| PVLA Palvella Therapeutics | Maintained: Buy | $49 → $212 | $148.21 | +43.04% | 2 | Dec 15, 2025 | |
| IFRX InflaRx | Maintained: Buy | $24 | $1.92 | +1,150.00% | 1 | Nov 10, 2025 | |
| VRCA Verrica Pharmaceuticals | Initiated Coverage: Buy | $19 | $6.84 | +177.78% | 1 | Nov 5, 2025 | |
| TSX: MDNA Medicenna Therapeutics Corp. | Initiated Coverage: Buy | $4.00 | $0.405 | +887.65% | 1 | Oct 14, 2025 | |
| ATYR aTyr Pharma | Downgraded: Hold | $1 | $0.5275 | +89.57% | 1 | Sep 15, 2025 | |
| CUE Cue Biopharma | Initiated Coverage: Buy | $4 | $25.39 | -84.25% | 1 | Aug 25, 2025 | |
| IRD Opus Genetics | Initiated Coverage: Buy | $5 | $4.00 | n/a | 1 | Jun 17, 2025 | |
| EDSA Edesa Biotech | Initiated Coverage: Buy | $9 | $8.19 | n/a | 1 | May 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $36 | $5.57 | n/a | 1 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $1.67 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $24 | $18.20 | n/a | 1 | Dec 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $0.8159 | n/a | 1 | Dec 17, 2024 |
Quoin Pharmaceuticals
May 4, 2026
Initiated Coverage: Buy
Price Target: $30
Current: $4.45
Upside: +574.16%
Acumen Pharmaceuticals
Dec 17, 2025
Initiated Coverage: Buy
Price Target: $6
Current: $2.36
Upside: +154.24%
Palvella Therapeutics
Dec 15, 2025
Maintained: Buy
Price Target: $49 → $212
Current: $148.21
Upside: +43.04%
InflaRx
Nov 10, 2025
Maintained: Buy
Price Target: $24
Current: $1.92
Upside: +1,150.00%
Verrica Pharmaceuticals
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $6.84
Upside: +177.78%
Medicenna Therapeutics Corp.
Oct 14, 2025
Initiated Coverage: Buy
Price Target: $4.00
Current: $0.405
Upside: +887.65%
aTyr Pharma
Sep 15, 2025
Downgraded: Hold
Price Target: $1
Current: $0.5275
Upside: +89.57%
Cue Biopharma
Aug 25, 2025
Initiated Coverage: Buy
Price Target: $4
Current: $25.39
Upside: -84.25%
Opus Genetics
Jun 17, 2025
Initiated Coverage: Buy
Price Target: $5
Current: $4.00
Upside: n/a
Edesa Biotech
May 23, 2025
Initiated Coverage: Buy
Price Target: $9
Current: $8.19
Upside: n/a
May 1, 2025
Initiated Coverage: Buy
Price Target: $36
Current: $5.57
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $6
Current: $1.67
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $24
Current: $18.20
Upside: n/a
Dec 17, 2024
Initiated Coverage: Buy
Price Target: $13
Current: $0.8159
Upside: n/a